SCHEMBL2270252

SCHEMBL2270252

O=C(O)c1ccc(CCc2ccccc2)cc1NC(=O)c1cccnc1N1CCCC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.62
HSD17B10 Q99714 1/20 0.62
MAPT P10636 3/20 0.52
ALDH1A1 P00352 2/20 0.51
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
SCN10A Q9Y5Y9 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
GAA P10253 1/20 0.46
KIF18A Q8NI77 2/20 0.45
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
CAPN1 P07384 1/20 0.43
CTSS P25774 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2276276 0.84 ALDH1A1 (0.54) TSHRHSD17B10MAPTALDH1A1KMT2A
SCHEMBL2274078 0.80 SMN1; SMN2 (0.49) TSHRMAPTALDH1A1KMT2AMEN1
SCHEMBL2268181 0.78 MAPT (0.52) MAPTALDH1A1KMT2AMEN1CYP1A2
SCHEMBL12118024 0.78 MAPT (0.46) MAPTALDH1A1KMT2AMEN1L3MBTL1
SCHEMBL2270880 0.75 ALOX15 (0.60) TSHRHSD17B10MAPTALDH1A1KMT2A
SCHEMBL3309889 0.74 KMT2A (0.70) TSHRHSD17B10MAPTALDH1A1KMT2A
SCHEMBL2276177 0.74 SLC16A3 (0.55) ALDH1A1L3MBTL1GAAKDM4ESMN1; SMN2
SCHEMBL2275852 0.74 MEN1 (0.55) MAPTALDH1A1KMT2AMEN1CYP1A2
SCHEMBL2276434 0.74 RAB9A (0.55) ALDH1A1KMT2AMEN1L3MBTL1GAA
SCHEMBL11008739 0.74 HSD17B10 (0.83) TSHRHSD17B10MAPTALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 TSHR 3951/4885HSD17B10 566/4885MAPT 4824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.